Abstract 2305
Background
This study aimed to examine the effects of progressive muscle relaxation (PMR) and mindfulness-based stress reduction (MBSR) on fatigue, coping styles and quality of life (QOL) in breast cancer patients receiving adjuvant paclitaxel regimen.
Methods
Participants (stages 1-3) were randomly assigned to either a 12-week (PMR) (n = 31), MBSR (n = 32) interventions or control group (CG) (n = 29). Participants in the intervention groups were instructed on PMR and MBSR, the steps of interventions were recorded a voice recorder, and were asked to listen the recorded audio files during exercises. Participants in the intervention groups continued PMR or MBSR 20 min. each day, totally 12 weeks at their home. The CG received only a single time attention placebo education (15 min.) on breast cancer before paclitaxel regimen. No intervention was applied to neither the interventions nor the control group until the follow-up assessment (week 14). Data collection tools included Patient Information Form, Brief Fatigue Inventory (BFI), Brief COPE, and the Functional Living Index-Cancer (FLIC). The data were collected at three time points including at baseline, week 12, and week 14. To analyze data repeated measures ANOVA and Kruskal Wallis tests were used.
Results
The BFI scores were significantly decreased in the MBSR, PMR groups when compared with the CG at week 12 and week 14 (p<.05). The use of emotional support, use of instrumental support, venting, positive reframing, and planning sub-dimension scores of Brief COPE were significantly higher in the MBSR, and PMR groups than the CG at week 12 and week 14 (p<.05). Besides, the humor and acceptance sub-dimension scores of Brief COPE were significantly higher in the MBSR, and PMR groups than the CG at week 14 (p<.05). Regarding FLIC, QOL scores, there were no significant differences between the groups at week 12 and week 14 (p>.05).
Conclusions
A brief, PMR and MBSR are simple and effective nursing interventions, initiated concurrently with adjuvant paclitaxel regimen that can be used to manage fatigue, and improve coping styles in patients with breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hacettepe University, Scientific Research Projects Coordination Unit (project THD-2018-17089).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract